MYOS Launches Optimized Re Muscle Health Website and HealthTrac App

(Click here for details)
The new Re Muscle Health HealthTrac app

(Click here for details)
Re Muscle Health Website

CEDAR KNOLLS, NJ--(Marketwired - July 22, 2015) -

MYOS Corporation (“MYOS” or the “Company”) (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today the launch of the new Rē Muscle Health™ website and HealthTrac app, providing customers the ability to set and track health and exercise goals, monitor diets and dietary programs, set consumption reminders and search and save hundreds of recipes.

Visit www.remusclehealth.com to learn more.

The Rē Muscle Health™ line of products feature non-GMO protein bars, shakes, pudding mixes and ready-to-eat powders. They are designed for individuals who want an all-natural product clinically proven to help rebuild, rejuvenate and maintain lean muscle.

Fortetropin® the active ingredient in Rē Muscle Health™ has been clinically shown to build healthy lean muscle in a double-blinded, randomized, placebo controlled study. Rē Muscle Health™ protein bars, shakes, and pudding mixes also have 20 grams of non-GMO protein to help protect, preserve and promote healthy lean muscle. Rē Muscle Health™ Bars, powders, meal replacement shakes and puddings can be used daily:

- To increase both muscle thickness and lean body mass
- For workout recovery -- protein helps promote muscle recovery and growth
- As a snack or meal replacement

The Rē Muscle Health™ Line of Products comes in six flavors, and can be ordered online at www.remusclehealth.com.

Peter Levy, President of MYOS, commented, “We are confident in the Rē Muscle Health™, product line, designed to rebuild, rejuvenate and deliver exceptional muscle health results. We believe, our ability to attract collaborative partners, establish retail and distribution networks can ultimately be achieved through the success of MYOS’ ecommerce and marketing strategy.”
Lindsey Penrose, Vice President of Business Development added, “MYOS is committed to providing our customers with mobile health and web-friendly solutions that complement the Rē Muscle Health program. We believe that this new, user-friendly “app” will support our customers in their goals to improve their quality of life through building and maintaining healthy lean muscle.

About MYOS Corporation

MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin®, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as “The Muscle Company,"™ visit www.myoscorp.com

About Rē Muscle Health™

The Rē Muscle Health™ series is the Company’s first branded line of muscle health products. This unique line of all-natural, Non-GMO products contain Fortetropin®, an egg-based, all natural myostatin inhibitor clinically proven to build healthy muscle. MYOS believes that Fortetropin®, as well as future products it envisions, will redefine existing standards for muscle health. The Rē Muscle Health™ product line is owned and sold directly by the Company at: www.remusclehealth.com

Forward-Looking Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin® and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, the successful launch and customer demand for our Rē Muscle Health™ and other products, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to collect our accounts receivable from our distributors, our ability to raise capital to fund continuing operations, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin® and Rē Muscle Health™, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ’s continuing listing standards, competition from other providers and products, risks in product development, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.